Latest news

• GSK partners with iTeos Therapeutics on next-gen immuno-oncology drug

  tiragolumab. In January, the US Food and Drug Administration (FDA) issued a BTD for tiragolumab in combination with Roche’s PD-L1 inhibitor Tecentriq (atezolizumab) in the first-line setting for

• Roche’s Tecentriq yields positive data in early stage NSCLC

  In January, Roche also received a breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA) for a combination of its investigational TIGIT blocker tiragolumab and Tecentriq (atezolizumab) for

• Roche’s tiragolumab plus Tecentriq combo wins FDA breakthrough therapy designation

  of its investigational TIGIT blocker tiragolumab and its PD-L1 inhibitor Tecentriq (atezolizumab). ... According to Roche, tiragolumab is the first anti-TIGIT molecule to win a BTD from the FDA.